Capivasertib(Truqap)
Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection
Manufacturer:
AstraZeneca
Validity period:
24 months
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of
a
pharmacist. For read by medical and pharmaceutical professionals only.
Truqap(Capivasertib) Instructions:Uses,Dosage, Side Effects
TRUQAP (capivasertib) is an orally administered kinase inhibitor developed by AstraZeneca. It received its initial U.S. approval in 2023. The drug specifically targets and inhibits all three isoforms (AKT1, AKT2, AKT3) of the serine/threonine kinase AKT. It is formulated as film-coated tablets available in two strengths and is used in combination with fulvestrant for a specific subset of advanced breast cancer.
Generic name
Capivasertib(Truqap)
English name
Capivasertib
Indications
Indicated in combination with fulvestrant for adult patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer harboring one or more alterations in PIK3CA, AKT1, or PTEN, as detected by an FDA-approved test, following disease progression on or after endocrine therapy.
Therapeutic Target
PIK3CA,AKT1,PTEN
Active Ingredients
Capivasertib
specifications
160mg * 64 tablets/box
Description
TRUQAP (Capivasertib) is an oral kinase inhibitor designed to target and inhibit the activity of AKT, a protein kinase involved in critical signaling pathways associated with cancer cell survival, growth, and proliferation. It is used in combination with fulvestrant for the treatment of specific types of breast cancer that harbor PIK3CA, AKT1, or PTEN alterations. The drug has demonstrated effectiveness in patients with HR-positive, HER2-negative breast cancer who have progressed on endocrine-based therapy or experienced recurrence within 12 months after completing adjuvant therapy.
Dosage and Administration
The recommended dose is 400 mg taken orally twice daily (approximately 12 hours apart) with or without food, administered for 4 consecutive days followed by 3 days off each week. Treatment should continue until disease progression or unacceptable toxicity. Dose modifications are recommended for adverse reactions and concomitant use with CYP3A inhibitors.
RELATED ARTICLES
How to Use Capivasertib
Capivasertib is an AKT kinase inhibitor that was approved for marketing in the United States in 2023. It is...
Wednesday, September 24th, 2025, 15:13
How to Use Capivasertib
Capivasertib is an AKT kinase inhibitor that was approved for marketing in the United States in 2023. It is...
Wednesday, September 24th, 2025, 14:54
Indications for Capivasertib
Capivasertib is a novel kinase inhibitor developed by AstraZeneca. It first received approval from the U.S. Food and...
Tuesday, September 23rd, 2025, 13:51
Contact Us
Mailbox:Info@Lucius.La
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved
